<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open Diabetes Res Care</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open Diabetes Res Care</journal-id><journal-id journal-id-type="hwp">bmjdrc</journal-id><journal-id journal-id-type="publisher-id">bmjdrc</journal-id><journal-title-group><journal-title>BMJ Open Diabetes Research &#x00026; Care</journal-title></journal-title-group><issn pub-type="epub">2052-4897</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31958297</article-id><article-id pub-id-type="pmc">6954806</article-id><article-id pub-id-type="publisher-id">bmjdrc-2019-000705corr1</article-id><article-id pub-id-type="doi">10.1136/bmjdrc-2019-000705corr1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group></article-categories><title-group><article-title>Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands</article-title></title-group><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>8</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>1</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>8</volume><issue>1</issue><elocation-id>e000705corr1</elocation-id><permissions><copyright-statement>&#x000a9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2020-08-01">http://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="bmjdrc-2019-000705corr1.pdf"/><related-article related-article-type="corrected-article" id="d35e68" ext-link-type="doi" xlink:href="10.1136/bmjdrc-2019-000705"/><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta><custom-meta><meta-name>access-type</meta-name><meta-value>free</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Hunt B, Malkin SJP, Moes RGJ, <italic>et al.</italic> Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. <italic>BMJ Open Diabetes Research and Care</italic> 2019;7:e000705. doi: 10.1136/bmjdrc-2019-000705.</p><p>This article was previously published with an error.</p><p>Details of author Bruce Wolffenbuttel have changed. The correct name is Bruce H R Wolffenbuttel and the correct affiliation is University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.</p></body></article>